You have 9 free searches left this month | to do more

rituximab

Rituximab is a drug used to treat Lymphoma, Chronic Lymphocytic Leukemia, Leukemia, and other conditions. Rituximab is being actively studied in 371 studies and prior, has been studied in 610.

Top SponsorsTop SitesTop Investigators
M.D. Anderson Cancer CenterM D Anderson Cancer CenterAjay Gopal
Hoffmann-La RocheMayo ClinicJulie M Vose, MD
National Cancer Institute (NCI)University of Texas MD Anderson Cancer CenterSteven P. Treon, MD, PhD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-11
Jan 11, 2022
F
Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
2021-09-03
Sep 3, 2021
N
Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +3 more
  • Bronx, New York
  • +3 more
2021-11-30
Nov 30, 2021
M
Not yet recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-24
Feb 24, 2021
U
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +8 more
  • Ixazomib Citrate
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-10-20
Oct 20, 2021
U
Terminated
  • Lymphoid Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021
N
Active, not recruiting
  • Ann Arbor Stage III Small Lymphocytic Lymphoma
  • +7 more
  • Washington, District of Columbia
  • +1 more
2021-08-12
Aug 12, 2021
M
Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-08
Feb 8, 2021
M
Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-04-27
Apr 27, 2021
N
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
2022-01-11
Jan 11, 2022
M
Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-16
Nov 16, 2021
A
Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +8 more
2022-01-06
Jan 6, 2022
M
Completed
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-09-28
Sep 28, 2021
O
Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Recurrent B Acute Lymphoblastic Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-27
Dec 27, 2021
M
Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-22
Nov 22, 2021
M
Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-09-13
Sep 13, 2021
L
Recruiting
  • ANCA Associated Vasculitis
  • Rituximab
  • +3 more
  • Leiden, Zuid-Holland, Netherlands
  • +1 more
2021-09-06
Sep 6, 2021
T
Recruiting
  • Pemphigus
  • Rituximab
  • IVIg
  • Central, Hong Kong
    Department of Medicine
2021-05-24
May 24, 2021
M
Recruiting
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-01-21
Jan 21, 2021
O
Active, not recruiting
  • Central Nervous System Lymphoma
  • Cincinnati, Ohio
  • +3 more
2021-09-15
Sep 15, 2021
N
Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
2021-12-15
Dec 15, 2021
U
Active, not recruiting
  • Lymphoid Leukemia
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin
2021-10-07
Oct 7, 2021
M
Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-01-12
Jan 12, 2021
W
Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-05-21
May 21, 2021
S
Terminated
  • Follicular Lymphoma
  • Frankston, Victoria, Australia
  • +4 more
2021-03-15
Mar 15, 2021